Marvella Elizabeth Ford

Dr. Marvella Elizabeth Ford


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
MRM. Patricia Rivera
M. Patricia Rivera
HKHormuzd A. Katki
Hormuzd A. Katki
NTNichole T. Tanner
Nichole T. Tanner
MTMatthew Triplette
Matthew Triplette
LSLori C. Sakoda
Lori C. Sakoda
MAMelinda C. Aldrich
Melinda C. Aldrich
Background: There are well-documented disparities in lung cancer outcomes across populations. Lung cancer screening (LCS) has the potential to reduce lung cancer mortality, but for this benefit to be realized by all high-risk groups, there must be careful attention to ensuring equitable access to this lifesaving preventive health measure. Objectives: To outline current knowledge on disparities in eligibility criteria for, access to, and implementation of LCS, and to develop an official American Thoracic Society statement to propose strategies to optimize current screening guidelines and resource allocation for equitable LCS implementation and dissemination. Methods: A multidisciplinary panel with expertise in LCS, implementation science, primary care, pulmonology, health behavior, smoking cessation, epidemiology, and disparities research was convened. Participants reviewed available literature on historical disparities in cancer screening and emerging evidence of disparities in LCS. Results: Existing LCS guidelines do not consider racial, ethnic, socioeconomic, and sex-based differences in smoking behaviors or lung cancer risk. Multiple barriers, including access to screening and cost, further contribute to the inequities in implementation and dissemination of LCS. Conclusions: This statement identifies the impact of LCS eligibility criteria on vulnerable populations who are at increased risk of lung cancer but do not meet eligibility criteria for screening, as well as multiple barriers that contribute to disparities in LCS implementation. Strategies to improve the selection and dissemination of LCS in vulnerable groups are described.

1 February 2013 in Health & Social Work
Verified
Journal Article
Closed access
PDF file
MFMarvella Elizabeth Ford
Marvella Elizabeth Ford
LSLaura A. Siminoff
Laura A. Siminoff
EPElisabeth Pickelsimer
Elisabeth Pickelsimer
AIArch G. Mainous III
Arch G. Mainous III
DSDaniel W. Smith
Daniel W. Smith
BTBarbara C. Tilley
Barbara C. Tilley
African Americans and Latinos are underrepresented in clinical trials. The purpose of this study was to elicit solutions to participation barriers from African Americans and Latinos. Fifty-seven adults (32 African Americans, 25 Latinos) ages 50 years and older participated. The Institute of Medicine's Unequal Treatment conceptual framework was used. Six racially/ethnically homogenous focus groups were conducted at five sites in three counties. Themes within groups and cross-cutting themes were identified. The NVIVO program was used for data classification. The data were reviewed for final coding and consensus. Shared solutions included addressing costs, recruiting in community contexts, conducting community and individualized patient education, and sharing patient safety information. Participants were unanimously in favor of clinical trials navigation recruitment interventions. Solutions specific to African Americans included diversifying research teams, recognizing past research abuses, and increasing community trust. Solutions specific to Latinos included providing low-literacy materials, providing Spanish-speaking clinicians and advocates, and clarifying that immigration status would neither be documented nor prevent participation. Solutions from African Americans and Latinos reflect their cultural backgrounds and historical experiences. The results suggest the importance of developing a tailored, barriers-focused navigation intervention to improve participation among diverse racial and ethnic populations.

17 February 2018 in Trials
Verified
Journal Article
Open access
PDF file
RARossybelle P Amorrortu
Rossybelle P Amorrortu
MAMariana Arevalo
Mariana Arevalo
SVSally W. Vernon
Sally W. Vernon
AIArch G. Mainous III
Arch G. Mainous III
VDVanessa Diaz
Vanessa Diaz
BTBarbara C. Tilley
Barbara C. Tilley
Despite efforts to increase diversity in clinical trials, racial/ethnic minority groups generally remain underrepresented, limiting researchers’ ability to test the efficacy and safety of new interventions across diverse populations. We describe the use of a systematic framework, intervention mapping (IM), to develop an intervention to modify recruitment behaviors of coordinators and specialist investigators with the goal of increasing diversity in trials conducted within specialty clinics. To our knowledge IM has not been used in this setting. The IM framework was used to ensure that the intervention components were guided by health behavior theories and the evidence. The IM steps consisted of (1) conducting a needs assessment, (2) identification of determinants and objectives, (3) selection of theory-informed methods and practical applications, (4) development and creation of program components, (5) development of an adoption and implementation plan, and (6) creation of an evaluation plan. The intervention included five educational modules, one in-person and four web-based, plus technical assistance calls to coordinators. Modules addressed the intervention rationale, development of clinic-specific plans to obtain minority-serving physician referrals, physician-centered and patient-centered communication, and patient navigation. The evaluation, a randomized trial, was recently completed in 50 specialty clinics and is under analysis. Using IM we developed a recruitment intervention that focused on building relationships with minority-serving physicians to encourage minority patient referrals. IM enhanced our understanding of factors that may influence minority recruitment and helped us integrate strategies from multiple disciplines that were relevant for our audience.

27 October 2018 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
KWKatherine R. Walter
Katherine R. Walter
MFMarvella Elizabeth Ford
Marvella Elizabeth Ford
MGMathew J. Gregoski
Mathew J. Gregoski
RKRita M. Kramer
Rita M. Kramer
KKKendrea D. Knight
Kendrea D. Knight
DTDavid P Turner
David P Turner
Purpose Lifestyle factors associated with personal behavior can alter tumor-associated biological pathways and thereby increase cancer risk, growth, and disease recurrence. Advanced glycation end products (AGEs) are reactive metabolites produced endogenously as a by-product of normal metabolism. A Western lifestyle also promotes AGE accumulation in the body which is associated with disease phenotypes through modification of the genome, protein crosslinking/dysfunction, and aberrant cell signaling. Given the links between lifestyle, AGEs, and disease, we examined the association between dietary-AGEs and breast cancer. Methods We evaluated AGE levels in bio-specimens from estrogen receptor-positive (ER+) and estrogen receptor-negative (ER−) breast cancer patients, examined their role in therapy resistance, and assessed the ability of lifestyle intervention to reduce circulating AGE levels in ER+ breast cancer survivors. Results An association between ER status and AGE levels was observed in tumor and serum samples. AGE treatment of ER+ breast cancer cells altered ERα phosphorylation and promoted resistance to tamoxifen therapy. In a proof of concept study, physical activity and dietary intervention was shown to be viable options for reducing circulating AGE levels in breast cancer survivors. Conclusions There is a potential prognostic and therapeutic role for lifestyle derived AGEs in breast cancer. Given the potential benefits of lifestyle intervention on incidence and mortality, opportunities exist for the development of community health and nutritional programs aimed at reducing AGE exposure in order to improve breast cancer prevention and treatment outcomes.

1 January 2017
Verified
Book Chapter
Closed access
ANA. Napoles
A. Napoles
ECE. Cook
E. Cook
TGT. Ginossar
T. Ginossar
KKK.D. Knight
K.D. Knight
MFMarvella Elizabeth Ford
Marvella Elizabeth Ford

1 March 2007 in Archives of Clinical Neuropsychology
Verified
Journal Article
Closed access
ABA Baird
A Baird
MFMarvella Elizabeth Ford
Marvella Elizabeth Ford
KPK Podell
K Podell
Numerous studies outline discrepancies in neuropsychological test profiles in African American and European American samples, despite similarities on major background factors. In our clinical sample of convenience, African American and European American older adults did not diverge on age, years of formal education, or global cognitive impairment. We predicted that ethnic groups would differ on a financial index, reading, and naming measures, but not on form discrimination and health problem-solving tasks. Results showed the expected patterns with the exception of form discrimination, which was lower in the African American group. Ethnicity no longer predicted standing on financial and nonverbal discrimination measures once we adjusted scores to equate for word-reading ability. In contrast, ethnicity status continued to explain significant variance in confrontation naming following adjustment for reading. When ethnic groups were subdivided by sex, European American men tended to have the highest scores of all four subgroups despite having equivalent levels of education. Therefore, future studies should examine the impact of cognitive activity throughout adulthood on real-world function and neuropsychological test performance among groups defined by both ethnicity and sex. In conclusion, in African American and European American elders seen for clinical assessment, literacy appeared to be associated with discrepant scores on a measure of real-world financial knowledge and skill, as well as with differences in verbal and nonverbal neuropsychological measures.